Literature DB >> 28005256

Risk factors for osteoporosis 2000-2012.

Robert A Adler1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 28005256     DOI： 10.1007/s12020-016-1209-x

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  10 in total

Review 1.  Association Between Hyponatremia, Osteoporosis, and Fracture: A Systematic Review and Meta-analysis.

Authors:  Sikarin Upala; Anawin Sanguankeo
Journal:  J Clin Endocrinol Metab       Date:  2016-02-25       Impact factor: 5.958

2.  Trends in hip fracture rates in Canada: an age-period-cohort analysis.

Authors:  Sonia Jean; Siobhan O'Donnell; Claudia Lagacé; Peter Walsh; Christina Bancej; Jacques P Brown; Suzanne Morin; Alexandra Papaioannou; Susan B Jaglal; William D Leslie
Journal:  J Bone Miner Res       Date:  2013-06       Impact factor: 6.741

3.  Time trends in osteoporosis risk factor profiles: a comparative analysis of risk factors, comorbidities, and medications over twelve years.

Authors:  Jakob Præst Holm; Lars Hyldstrup; Jens-Erik Beck Jensen
Journal:  Endocrine       Date:  2016-05-13       Impact factor: 3.633

Review 4.  Laboratory testing for secondary osteoporosis evaluation.

Authors:  Robert A Adler
Journal:  Clin Biochem       Date:  2012-02-04       Impact factor: 3.281

5.  Trends in Media Reports, Oral Bisphosphonate Prescriptions, and Hip Fractures 1996-2012: An Ecological Analysis.

Authors:  Smita Jha; Zhong Wang; Nicholas Laucis; Timothy Bhattacharyya
Journal:  J Bone Miner Res       Date:  2015-07-14       Impact factor: 6.741

6.  Fracture liaison service: impact on subsequent nonvertebral fracture incidence and mortality.

Authors:  Kirsten M B Huntjens; Tineke A C M van Geel; Joop P W van den Bergh; Svenhjalmar van Helden; Paul Willems; Bjorn Winkens; John A Eisman; Piet P Geusens; Peter R G Brink
Journal:  J Bone Joint Surg Am       Date:  2014-02-19       Impact factor: 5.284

Review 7.  Bisphosphonates and atypical femoral fractures.

Authors:  Robert A Adler
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2016-12       Impact factor: 3.243

8.  Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women.

Authors:  Cara Tannenbaum; Julie Clark; Kevin Schwartzman; Sylvan Wallenstein; Robert Lapinski; Diane Meier; Marjorie Luckey
Journal:  J Clin Endocrinol Metab       Date:  2002-10       Impact factor: 5.958

Review 9.  FRAX updates 2016.

Authors:  Eugene V McCloskey; Nicholas C Harvey; Helena Johansson; John A Kanis
Journal:  Curr Opin Rheumatol       Date:  2016-07       Impact factor: 5.006

Review 10.  Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.

Authors:  Aliya A Khan; Archie Morrison; David A Hanley; Dieter Felsenberg; Laurie K McCauley; Felice O'Ryan; Ian R Reid; Salvatore L Ruggiero; Akira Taguchi; Sotirios Tetradis; Nelson B Watts; Maria Luisa Brandi; Edmund Peters; Teresa Guise; Richard Eastell; Angela M Cheung; Suzanne N Morin; Basel Masri; Cyrus Cooper; Sarah L Morgan; Barbara Obermayer-Pietsch; Bente L Langdahl; Rana Al Dabagh; K Shawn Davison; David L Kendler; George K Sándor; Robert G Josse; Mohit Bhandari; Mohamed El Rabbany; Dominique D Pierroz; Riad Sulimani; Deborah P Saunders; Jacques P Brown; Juliet Compston
Journal:  J Bone Miner Res       Date:  2015-01       Impact factor: 6.741
  10 in total
  2 in total

1.  Association of serum uric acid levels with osteoporosis and bone turnover markers in a Chinese population.

Authors:  Dan-Dan Yan; Jie Wang; Xu-Hong Hou; Yu-Qian Bao; Zhen-Lin Zhang; Cheng Hu; Wei-Ping Jia
Journal:  Acta Pharmacol Sin       Date:  2017-12-14       Impact factor: 6.150

2.  Comparative impact of systemic delivery of atorvastatin, simvastatin, and lovastatin on bone mineral density of the ovariectomized rats.

Authors:  Mostafa Shahrezaee; Ahmad Oryan; Farshid Bastami; Sepanta Hosseinpour; Mohammad Hossein Shahrezaee; Amir Kamali
Journal:  Endocrine       Date:  2018-01-25       Impact factor: 3.633
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.